Frontiers in Pediatrics (Aug 2023)

Severe gastrointestinal involvement in pediatric IgA vasculitis: a retrospective single-center cohort study in China

  • Yifan Li,
  • Xiaomei Zhang,
  • Haimei Liu,
  • Guomin Li,
  • Wanzhen Guan,
  • Tao Zhang,
  • Qiaoqian Zeng,
  • Yinv Gong,
  • Hong Xu,
  • Hong Xu,
  • Li Sun

DOI
https://doi.org/10.3389/fped.2023.1194214
Journal volume & issue
Vol. 11

Abstract

Read online

ObjectivesThe study aimed to describe the characteristics of gastrointestinal (GI) involvement in a cohort of hospitalized children with IgA vasculitis (IgAV) in China.MethodWe reviewed the records of hospitalized IgAV patients from January 2014 to December 2020 at one tertiary medical center. The patients were divided into the severe GI group and the non-severe GI group according to the presence of massive GI bleeding and complications. The clinical manifestations, laboratory factors, and treatment were analyzed between the two groups.ResultsA total of 1,179 patients were hospitalized due to IgAV. GI involvement was noted in 50% (589) of the patients, of whom 288 (48.9%) had severe GI involvement. GI complications were observed in 34 patients with IgAV with GI involvement. Rare onset age (<3 years or within 13–17 years), purpura above the waist, vomiting, high neutrophil-to-lymphocyte ratio, and decreased serum albumin were factors associated with severe GI involvement. Frequencies of renal involvement and biopsy-proven nephritis were higher in the severe GI group. The most commonly used medications were corticosteroids (100.0%) in the severe GI group. The maximum corticosteroid dose was higher (2.9 vs. 2.0 mg/kg), and more second-line therapies were needed (30.9% vs. 16.94%) in the severe GI group.ConclusionsSevere GI involvement in children is common in our center. Rare onset age, purpura above the waist, vomiting, high neutrophil-to-lymphocyte ratio, and decreased serum albumin are associated with severe GI involvement. Patients with severe GI involvement need higher doses of corticosteroids and second-line therapy.

Keywords